Peptides by condition · Muscles, bones, joints and skin
Peptides studied for mitochondrial and muscle disease
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 8 study pages on mitochondrial and muscle disease: 8 in people (5 of them meta-analyses or randomized trials). They studied 2 compounds, with this many study pages each: SS-31 7 and Follistatin-344 1.
What the research on mitochondrial and muscle disease looks like
Read the design before any result. All 8 of these studies were in people, the largest with 218 people. A small trial is a first test, and its result needs larger trials to be confirmed.
Mitochondrial diseases are rare inherited conditions in which the cell’s energy makers, the mitochondria, fail, often hitting the muscles, the heart and the eyes hardest. They include Barth syndrome, which affects boys and men and weakens the heart and the skeletal muscles, primary mitochondrial myopathy, which brings weakness and deep tiredness with effort, and Leber hereditary optic neuropathy, which takes central vision. Muscular dystrophies are a separate family of inherited muscle-wasting diseases, and one of the studies here is in Becker muscular dystrophy.
Because these diseases are rare, the trials are small and often measure how far a person walks in six minutes, muscle strength and fatigue scores. Some use a crossover design, giving each person the drug and the placebo in turn.
With a handful of patients per trial, a single result can swing either way, so look at whether a gain held up over months and in more than one trial. Open-label results, where everyone knows they are on the drug, are weaker.
The 8 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
SS-31
7 in peopleFor mitochondrial and muscle disease, 7 of our study pages are filed under SS-31: 5 randomized trials, 1 clinical trial and 1 observational study in people. The largest in people enrolled 218 people and was published in 2023. They were published from 2018 to 2024, in Neurology, Ophthalmology, Orphanet J Rare Dis and Genet Med.
FDA-approved, with a use tied to mitochondrial and muscle disease on its label: Forzinity (injection) for improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg (an accelerated approval; it may depend on a confirmatory trial).
- Randomized trial in people · 218 people · 2023SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial
- Randomized trial in people · 36 people · 2018SS-31: walk distance rose with dose in 5-day MMPOWER trial
- Randomized trial in people · 12 people · 2024SS-31 (elamipretide) eye drops missed main vision goal in LHON trial
- Randomized trial in people · 12 people · 2023SS-31: wearable data grouped responders with 100% accuracy
- Randomized trial in people · 12 people · 2021SS-31: no 12-week benefit, walk gains by 36 weeks open-label
- Clinical trial in people · 2024SS-31: 96.1 m longer 6-minute walk at 168 weeks in TAZPOWER
- Observational study in people · 2022SS-31: 79.7 m better walk test vs untreated in Barth syndrome
Follistatin-344
1 in peopleFor mitochondrial and muscle disease, 1 of our study pages is filed under Follistatin-344: 1 clinical trial in people. It enrolled 6 people and was published in 2015, in Mol Ther.
Follistatin-344 has no FDA-approved product: Drugs@FDA lists no application for follistatin in any form.
- Clinical trial in people · 6 people · 2015Follistatin-344 gene therapy: walk gains in some Becker patients
Side by side
For the 2 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| SS-31 | 7 | 0 | 218 | Approved, a use tied to it |
| Follistatin-344 | 1 | 0 | 6 | Not approved |
- In people
- 7
- Animals or cells
- 0
- Largest in people
- 218
- FDA
- Approved, a use tied to it
- In people
- 1
- Animals or cells
- 0
- Largest in people
- 6
- FDA
- Not approved
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trialThe trial lasted 24 weeks and tested a single dose in people with this specific genetic muscle condition, and 94% of them were White. It does not show how elamipretide does in other conditions or over longer periods.
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialThis was a very small, single-center trial in 1 genetic form of LHON. The visual field result came from an analysis planned after the fact, and the gains in the open-label extension had no vehicle comparison.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for mitochondrial and muscle disease?
Our 8 study pages on mitochondrial and muscle disease are filed under 2 compounds, with this many each: SS-31 7 and Follistatin-344 1. SS-31 has the most.
Have any been tested in people with mitochondrial and muscle disease?
Yes: all 8 were in people, 5 of them meta-analyses or randomized trials (SS-31). The largest enrolled 218 people: “SS-31: no gain in walk distance or fatigue in the MMPOWER-3 trial” (2023).
Is any peptide FDA-approved for mitochondrial and muscle disease?
Yes, with a use tied to mitochondrial and muscle disease on their FDA labels: SS-31 as Forzinity. 1 other compound here with an FDA record has no use tied to it.
How large were the studies in people on mitochondrial and muscle disease?
Of the 8 in people, 6 give their size on our pages: 1 had 100 to 999 and 5 had fewer than 100. The largest, a randomized trial from 2023, enrolled 218.
What is the newest study on mitochondrial and muscle disease here?
Of our study pages on mitochondrial and muscle disease, the newest is “SS-31 (elamipretide) eye drops missed main vision goal in LHON trial”, a randomized trial in people published in 2024.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.